Pyxis Oncology, Inc.

Pyxis Oncology, Inc. (PYXS) priced its initial public offering on Oct 8, 2021 at $16.00 per share, within its $14.00–$16.00 range, raising $168M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $523.7M. BofA Securities was lead-left underwriter, joined by Jefferies, Credit Suisse and William Blair. Sidley Austin advised the company and Latham & Watkins advised the underwriters.

Pyxis Oncology, Inc. is a preclinical oncology company developing therapeutics for difficult-to-treat cancers. Since its 2019 launch it has built a portfolio of antibody drug conjugate candidates and monoclonal antibody discovery programs, studied alone and in combination.

Status

IPO

Ticker

PYXS

Exchange

Nasdaq Global Select

Priced

Oct 8, 2021

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$168M

Market cap at IPO price

$523.7M

First filed

Sep 17, 2021

Underwriters

BofA Securities, Jefferies, Credit Suisse and William Blair

Company counsel

Sidley Austin

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.